On the other hand, although BCMA acts as a ligand for BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), inhibitors of these two cytokines, which play key roles in myeloma cell proliferation and viability, have demonstrated poor results in MM trials [47,48,49]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.